COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Zhong et al.
, COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective..
, Lancent Rheumatology, doi:10.1016/S2665-9913(20)30227-7
Rheumatic disease patients on HCQ had a lower risk of COVID-19 than those on other disease-modifying anti-rheumatic drugs, OR 0.09 (0.01–0.94), p=0.044 after adjusting for age, sex, smoking, systemic lupus erythematosus, infection in other family members, and comorbidities. 43 patients with rheumatic disease and COVID-19 exposure.
risk of case, 91.0% lower, RR 0.09, p = 0.04, treatment 7 of 16 (43.8%), control 20 of 27 (74.1%), NNT 3.3, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhong et al., 3 Jul 2020, retrospective, database analysis, China, peer-reviewed, 20 authors.
COVID-19 in patients with rheumatic disease in Hubei
province, China: a multicentre retrospective
Jixin Zhong, Guifen Shen, Huiqin Yang, Anbin Huang, Xiaoqi Chen, Li Dong, Bin Wu, Anbin Zhang, Linchong Su, Xiaoqiang Hou, Shulin Song,
Huiling Li, Wenyu Zhou, Tao Zhou, Qin Huang, Aichun Chu, Zachary Braunstein, Xiaoquan Rao, Cong Ye, Lingli Dong
Background In the ongoing COVID-19 pandemic, the susceptibility of patients with rheumatic diseases to COVID-19
remains unclear. We aimed to investigate susceptibility to COVID-19 in patients with autoimmune rheumatic diseases
during the ongoing COVID-19 pandemic.
Methods We did a multicentre retrospective study of patients with autoimmune rheumatic diseases in Hubei province,
the epicentre of the COVID-19 outbreak in China. Patients with rheumatic diseases were contacted through an
automated telephone-based survey to investigate their susceptibility to COVID-19. Data about COVID-19 exposure or
diagnosis were collected. Families with a documented history of COVID-19 exposure, as defined by having at least one
family member diagnosed with COVID-19, were followed up by medical professionals to obtain detailed information,
including sex, age, smoking history, past medical history, use of medications, and information related to COVID-19.
Findings Between March 20 and March 30, 2020, 6228 patients with autoimmune rheumatic diseases were included
in the study. The overall rate of COVID-19 in patients with an autoimmune rheumatic disease in our study population
was 0·43% (27 of 6228 patients). We identified 42 families in which COVID-19 was diagnosed between Dec 20, 2019,
and March 20, 2020, in either patients with a rheumatic disease or in a family member residing at the same physical
address during the outbreak. Within these 42 families, COVID-19 was diagnosed in 27 (63%) of 43 patients with a
rheumatic disease and in 28 (34%) of 83 of their family members with no rheumatic disease (adjusted odds ratio
[OR] 2·68 [95% CI 1·14–6·27]; p=0·023). Patients with rheumatic disease who were taking hydroxychloroquine had a
lower risk of COVID-19 infection than patients taking other disease-modifying anti-rheumatic drugs (OR 0·09
[95% CI 0·01–0·94]; p=0·044). Additionally, the risk of COVID-19 was increased with age (adjusted OR 1·04 [95% CI
Interpretation Patients with autoimmune rheumatic disease might be more susceptible to COVID-19 infection than
the general population.
Funding National Natural Science Foundation of China and the Tongji Hospital Clinical Research Flagship Program.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.